Anthem Biosciences has raised Rs 1,016 crore from anchor investors, ahead of its initial share-sale opening for public subscription.
Some of the investors that participated in the anchor book are—Abu Dhabi Investment Authority, Government Pension Fund Global, Eastspring Investments, Amundi Funds, PineBridge Global Funds and Societe Generale, HDFC MF (MF), ICICI Prudential MF, Axis MF, UTI MF, Quant MF and Motilal Oswal MF, according to a circular uploaded on BSE's website late night on Friday.
As per the circular, the company has allocated 1.78 crore equity shares to 60 funds at Rs 570 apiece, which is the upper end of the price band. This aggregates the transaction size to Rs 1,016 crore.
The Rs 3,395 crore IPO of the Bengaluru-based firm will open for public subscription on July 14 and close on July 16. The price band has been set at Rs 540-570 per share.
Since the IPO is entirely an offer-for-sale, the company will not receive any funds from the issue and the proceeds will go to the selling shareholders.
Anthem is into innovation-driven and technology-focused Contract Research, Development and Manufacturing Organization with fully integrated operations spanning across drug discovery, development and manufacturing.
It also manufactures and sells complex specialised fermentation-based Active Pharmaceutical Ingredients, including probiotics, enzymes, peptides, nutritional actives, vitamin analogues and biosimilars.
Sai Life Sciences Ltd, Syngene International, Suven Life Sciences and Divi's Laboratories are the listed peers of Anthem Biosciences.
JM Financial, Citigroup Global Markets India, J P Morgan India and Nomura Financial Advisory and Securities (India) are the book-running lead managers for the issue.
Comprehensive Budget 2026 coverage, LIVE TV analysis, Stock Market and Industry reactions, Income Tax changes and Latest News on NDTV Profit.
